Update on HIV protease inhibitors.
Vella
S
S
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D016049:Didanosine / Q000008:administration & dosage / Q000627:therapeutic use; D015195:Drug Design; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D016333:HIV Protease / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir; D007546:Isoquinolines / Q000009:adverse effects / Q000627:therapeutic use; D010766:Phosphorylation; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use; D019438:Ritonavir; D019258:Saquinavir; D013379:Substrate Specificity; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D014633:Valine / Q000009:adverse effects / Q000627:therapeutic use; D016047:Zalcitabine / Q000008:administration & dosage / Q000627:therapeutic use; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D011725:Pyridines; D011804:Quinolines; D013844:Thiazoles; D015215:Zidovudine; D019469:Indinavir; D016047:Zalcitabine; D016333:HIV Protease; D014633:Valine; D016049:Didanosine; D019258:Saquinavir; D019438:Ritonavir